UnitedHealth Is the World's Fourth-Largest Company by Revenue. What Does That Scale Mean for Healthcare?

Farzin Espahani

Principal Consultant, VHealth Partners

Published July 31, 2026

UnitedHealth Group generated more revenue in 2025 than Saudi Aramco, Apple, McKesson, Alphabet and CVS Health.

With $447.6 billion in annual revenue, UnitedHealth moved from seventh to fourth place on the 2026 Fortune Global 500. Only Amazon, Walmart and China's State Grid reported more revenue.

The ranking confirms how large UnitedHealth has become. It also gives policymakers, employers, providers and consumers a reason to examine how that scale is governed and whether the benefits of integration can be measured.

UnitedHealth now operates across health insurance, care delivery, pharmacy benefits, prescription fulfillment, data, technology, payment infrastructure and administrative services. Its financial performance depends on millions of decisions involving medical costs, reimbursement, referrals, claims, pharmacy spending, risk adjustment and government-program payments.

Those decisions reach patients and members through premiums, benefits, provider networks, prior authorization, prescription access and medical bills.

UnitedHealth's position among the world's largest companies

The Fortune Global 500 ranks public and private companies by annual revenue. The 500 companies on the 2026 list generated a combined $43.1 trillion during the 2025 fiscal year.

UnitedHealth reported $447.6 billion in revenue, an increase of 11.8% from 2024. Fortune also listed approximately $12.1 billion in profit.

Healthcare was the fifth-largest sector represented on the list, with 31 companies. Five healthcare organizations were among the 21 largest companies in the world by revenue:

The ranking reflects the amount of money moving through the American healthcare system. Revenue alone cannot show whether that spending produced better access, lower total cost, stronger clinical outcomes or a simpler experience for patients.

Revenue measures economic scale. Healthcare performance requires additional measures.

Revenue growth and operating performance moved in different directions

UnitedHealth's 2025 financial results show why revenue should not be treated as a complete measure of performance.

According to the company's 2025 annual filing, consolidated revenue increased 12% to $447.6 billion. Earnings from operations fell 41%, from $32.3 billion in 2024 to $19.0 billion in 2025. The consolidated operating margin declined from 8.1% to 4.2%.

UnitedHealthcare's operating margin fell from 5.2% to 2.7%. Optum's operating margin declined from 6.6% to 3.5%.

These results followed a difficult year involving higher-than-expected medical costs, pressure within Medicare Advantage and operating challenges across parts of Optum Health. Revenue continued to grow while the economics supporting that revenue weakened.

Performance improved during the second quarter of 2026. UnitedHealth reported $112 billion in quarterly revenue, $8 billion in operating earnings and approximately $5.5 billion in net earnings. The company also raised its full-year adjusted earnings guidance to between $19.50 and $20 per share while maintaining annual revenue guidance above $439 billion.

UnitedHealth Group reported those results on July 16, 2026.

The recovery matters, but the Fortune ranking is based on 2025 revenue. The ranking does not measure current operating quality, healthcare affordability or the durability of UnitedHealth's margin recovery.

How UnitedHealth's integrated model works

UnitedHealth Group operates through two primary businesses.

UnitedHealthcare provides health benefits across employer, individual, Medicare and Medicaid markets. Optum operates across care delivery, pharmacy services, analytics, technology and healthcare administration.

In 2025, UnitedHealthcare reported $344.9 billion in segment revenue. Optum reported $270.6 billion. Those figures cannot be added together to calculate consolidated revenue because a substantial amount of business occurs between the two divisions.

UnitedHealth reported approximately $168 billion in corporate and intersegment eliminations for 2025. Its annual filing explains that these internal transactions include:

• →Pharmacy products and services provided by Optum Rx to UnitedHealthcare members
• →Care delivery and care-management services provided by Optum Health
• →Technology, consulting and information services provided by Optum Insight

The transactions are recorded using management's estimate of fair value and then eliminated from the consolidated financial statements to prevent double counting.

Internal transactions are expected within an integrated company. At UnitedHealth's scale, they create a substantial governance obligation. Leadership, regulators and customers need enough visibility to understand how internal prices are established, whether affiliated entities receive preferential treatment and where earnings are generated across the organization.

Consolidated reporting may comply with accounting requirements while still providing limited visibility into how money moves among business units. That visibility affects employers negotiating benefits, providers evaluating contracts, policymakers overseeing government programs and consumers trying to understand rising healthcare costs.

The operating case for vertical integration

UnitedHealth argues that combining insurance, care delivery, pharmacy services and technology allows the company to coordinate care, use data more effectively and move more patients into value-based arrangements.

There is a reasonable operating basis for that argument.

Fragmented healthcare creates duplicated work, incomplete patient information, poor handoffs and delays. An integrated organization may be able to connect claims data, pharmacy activity and clinical information earlier. It may also have more influence over care management, preventive interventions and the site where care is delivered.

During two congressional hearings in January 2026, UnitedHealth Chief Executive Officer Stephen Hemsley defended the company's structure on those grounds. He argued that coordination across insurance, care and pharmacy can improve the patient experience and produce greater value.

The value of integration should be supported by measurable outcomes. Those measures should include total cost of care, access, clinical quality, member experience, provider burden and administrative accuracy.

Company size cannot answer those questions by itself.

Why vertical integration is receiving bipartisan scrutiny

The same structure that may support coordination can create conflicts of interest.

An insurer that owns providers, pharmacies, a pharmacy benefit manager and healthcare technology assets may be able to direct business toward its own companies. It may also determine reimbursement, network participation and administrative requirements for organizations that compete with those companies.

These concerns received bipartisan attention during two House hearings on January 22, 2026. Executives from UnitedHealth, CVS Health, Elevance Health, The Cigna Group and Ascendiun appeared before lawmakers.

In February 2026, Senators Elizabeth Warren and Josh Hawley introduced the Break Up Big Medicine Act.

If enacted, the proposal would prohibit a parent company from simultaneously owning a health insurer or pharmacy benefit manager and a medical provider or management-services organization. Affected companies would generally have one year to comply.

The legislation remains a proposal. Its bipartisan sponsorship shows that vertical integration is receiving attention across party lines.

Policymakers are trying to determine whether integration produces savings and better coordination that reach consumers, or whether it reduces competition and moves revenue among affiliated businesses without lowering total healthcare costs.

Answering that question will require more detailed evidence than consolidated revenue or isolated examples of successful integration.

Why the claim that UnitedHealth has only 10 subsidiaries is misleading

The discrepancy points to a wider transparency problem. Investors and regulators may receive the disclosures required under securities rules while still lacking a complete, accessible map of UnitedHealth's legal entities, business functions and financial relationships.

What healthcare leaders should measure

Payer and provider leaders do not need to wait for the outcome of proposed legislation to improve their controls.

Large integrated healthcare organizations should be able to answer six operating questions.

1. How are internal prices established?

Transactions among insurance, care delivery, pharmacy and technology businesses should follow documented methodologies with appropriate financial, legal and compliance review.

2. Are affiliated and unaffiliated providers treated consistently?

Organizations should monitor reimbursement, referrals, prior authorization, denial rates, payment timing and network decisions for material differences.

3. Do members and patients receive measurable value?

Integration should produce evidence of lower total cost, better access, fewer administrative delays, stronger quality and a more consistent experience.

4. Can leaders trace financial performance to its source?

Consolidated results should be supported by enough business-unit visibility to identify revenue leakage, cost shifting, workflow failures and emerging compliance exposure.

5. Are important decisions auditable?

Decisions involving networks, claims, pharmacy services, risk adjustment and government-program payments need clear ownership, documentation and an evidence trail.

6. Who reviews conflicts involving affiliated businesses?

Oversight should include legal, compliance, finance, clinical and operational judgment. High-stakes decisions should remain subject to accountable human review, including when automated or artificial intelligence-supported systems are involved.

These controls apply beyond UnitedHealth. Any payer, provider or healthcare-services company operating across multiple parts of the healthcare system faces similar questions, even at a smaller scale.

What UnitedHealth's scale should require

UnitedHealth's fourth-place ranking confirms its commercial reach and the economic weight of healthcare within the global economy.

The remaining questions concern what that reach produces for patients, employers, providers and public programs.

Answering them requires transparent financial relationships, consistent workflows, documented controls and credible measures of affordability, access, quality and administrative burden.

Revenue establishes how large an organization has become. Long-term trust will depend on what the organization can document and demonstrate about how that scale is used.

Frequently asked questions

Sources and methodology

This article uses the following publicly available sources:

• →2026 Fortune Global 500
• →UnitedHealth Group 2025 annual filing
• →UnitedHealth Group significant-subsidiaries exhibit
• →UnitedHealth Group second-quarter 2026 results
• →House Ways and Means Committee hearing with health insurance executives
• →Break Up Big Medicine Act announcement
• →Sunlight Report on UnitedHealth Group
• →Becker's Healthcare ranking summary

Financial figures are rounded where appropriate. The Fortune ranking measures revenue and should not be interpreted as a ranking of care quality, affordability, market capitalization or consumer value.

Farzin Espahani

Principal Consultant, VHealth Partners

Farzin Espahani is Principal Consultant at VHealth Partners and a former General Manager of Health and Medicare Insurance at QuinStreet. He writes about healthcare operations, payer economics, regulated growth, compliance and the systems that affect members, patients and providers.